Chugai Pharmaceutical (OTCMKTS:CHGCY) Shares Gap Down – Here’s What Happened

Chugai Pharmaceutical Co., Ltd. Unsponsored ADR (OTCMKTS:CHGCY)’s stock price gapped down prior to trading on Monday . The stock had previously closed at $28.90, but opened at $26.72. Chugai Pharmaceutical shares last traded at $27.48, with a volume of 26,567 shares trading hands.

Wall Street Analyst Weigh In

Several research analysts have commented on CHGCY shares. UBS Group raised Chugai Pharmaceutical to a “strong-buy” rating in a research note on Tuesday, January 27th. Smbc Nikko Sec. raised shares of Chugai Pharmaceutical to a “strong-buy” rating in a report on Wednesday, February 25th. Two analysts have rated the stock with a Strong Buy rating, According to MarketBeat.com, the stock presently has an average rating of “Strong Buy”.

Chugai Pharmaceutical Stock Performance

The firm has a market cap of $91.52 billion, a price-to-earnings ratio of 31.97 and a beta of 0.69. The business has a fifty day simple moving average of $29.29 and a 200-day simple moving average of $26.59.

Chugai Pharmaceutical (OTCMKTS:CHGCY) last released its quarterly earnings results on Thursday, January 29th. The company reported $0.25 earnings per share for the quarter. Chugai Pharmaceutical had a return on equity of 22.00% and a net margin of 34.47%.The company had revenue of $2.25 billion for the quarter. On average, equities analysts anticipate that Chugai Pharmaceutical Co., Ltd. Unsponsored ADR will post 0.74 earnings per share for the current year.

About Chugai Pharmaceutical

Chugai Pharmaceutical Co, Ltd. is a Japan-based biopharmaceutical company headquartered in Tokyo that focuses on the discovery, development, manufacture and marketing of prescription medicines. The company develops both biologics and small-molecule therapies, with particular emphasis on oncology and immunology as well as treatments for bone and metabolic disorders. Chugai’s activities span the full drug lifecycle from early research and clinical development through regulatory approval, manufacturing and post-marketing support.

Chugai is known for its research-driven approach and its work on monoclonal antibodies and other biologic therapeutics.